erythromycin gluceptate - Profile

What are the generic drug sources for erythromycin gluceptate and what is the scope of patent protection?

Erythromycin gluceptate is the generic ingredient in one branded drug marketed by Dista and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for erythromycin gluceptate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for erythromycin gluceptate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dista	ILOTYCIN GLUCEPTATE	erythromycin gluceptate	INJECTABLE;INJECTION	050370-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Dista	ILOTYCIN GLUCEPTATE	erythromycin gluceptate	INJECTABLE;INJECTION	050370-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Dista	ILOTYCIN GLUCEPTATE	erythromycin gluceptate	INJECTABLE;INJECTION	050370-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Erythromycin gluceptate Market Analysis and Financial Projection

Last updated: April 25, 2026

Erythromycin Gluceptate: Investment Scenario and Fundamentals Analysis

What is erythromycin gluceptate and where does it sit commercially?

Erythromycin gluceptate is an oral prodrug of erythromycin formulated as the “gluceptate” salt. It is used as an antibacterial agent in settings where an erythromycin-class product is appropriate and where the specific salt/prodrug form has been used historically for improved tolerability and/or formulation characteristics versus base erythromycin in some markets.

Commercial framing (what matters for investors):

• Therapy area: Antibiotics (macrolide class).
• Mechanism: Erythromycin-class antibacterial activity (prodrug converts to active erythromycin).
• Primary investment driver: Patent exclusivity strength (if any) and market accessibility in key geographies versus mature generics.
• Secondary driver: Formulation lifecycle (switching salt forms, dosing convenience) and brand persistence in local markets.

Observed market reality for this drug type:

• Erythromycin products are generally mature, and many markets price primarily around generics.
• For a prodrug/salt like erythromycin gluceptate, the investment question typically hinges on whether there is still any enforceable IP (composition, manufacturing, polymorphs, process) and whether the product remains protected or differentiated in practice.

Because the prompt does not include a specific target geography, label/strength, or patent family you are underwriting, a complete “fundamentals + patent landscape + pipeline competition” investment memo cannot be produced to required precision.

---

What are the fundamentals that determine revenue durability?

For erythromycin gluceptate, revenue durability is governed by standard antibiotic commercial fundamentals:

1) Price and substitution risk

• High substitution pressure: Other macrolides and generic erythromycin formulations often compete directly.
• Salt/prodrug differentiation erodes under generic pressure: When the active moiety is known, regulators and payers typically focus on bioequivalence and overall cost.

Investor implication: Even if there is a brand, economics tend to compress unless IP prevents generic entry or the product is protected by regulatory exclusivity tied to a specific approved version (rare in mature products).

2) Guideline and resistance-driven demand

• Macrolide use depends on local resistance patterns and guideline recommendations.
• In many regions, macrolides face periodic shifts in preferred status versus alternatives such as beta-lactams, lincosamides, or other antibiotic classes depending on indication.

Investor implication: Demand is usually stable only in narrow indications or in geographies where macrolides remain a standard option.

3) Channel and tender dynamics

• Many antibiotic markets behave like tender markets or list-price markets with heavy payer leverage.
• Hospital formularies and procurement protocols can move demand quickly among competing generics.

Investor implication: Sustained share often depends on supply reliability, lowest-cost positioning, and contracting.

---

What does the patent and exclusivity profile likely mean for underwriting?

A complete patent exclusivity analysis requires:

• the specific marketed product identifiers (strengths, dosage form, label indications),
• the jurisdictions underwrite (US, EP, JP, CN, etc.),
• and the exact patent families mapped to that marketed form.

Without those inputs, the analysis cannot be completed to an “actionable for investment decision” standard under a patent analyst workflow.

Given the molecule’s class maturity, the typical outcome for erythromycin-derived oral products is:

• composition/process families from earlier eras are frequently near or past expiration,
• the investable protection, when present at all, usually comes from later formulation/process improvements (which must be confirmed for this exact product form and geography).

---

How does clinical and regulatory status affect the risk profile?

Clinical and regulatory factors for erythromycin gluceptate generally translate into:

• Regulatory pathway for competitors: If erythromycin gluceptate is already established, follow-on entrants can often file generics/biosimilar-type analogs (for antibiotics, typically generic routes). This pushes competition toward cost.
• Label breadth and indication anchoring: Any remaining branded advantage depends on what indications the product is actually marketed for in each geography and whether those indications remain in guideline use.

Investor implication: Regulatory status matters less than enforceable exclusivity and current market uptake, but it does shape the speed of generic entry and substitution.

---

What are the core investment scenarios and how should they be structured?

Below are the scenario frameworks that typically apply to mature antibiotics and salt/prodrug variants like erythromycin gluceptate. These are structured as underwriting paths rather than claims about current IP status.

Scenario A: Generic-dominant market (low margin, limited moat)

When it fits:

• No enforceable composition/process protection for the exact marketed salt/form or geography.
• Competitive generic erosion is already underway.

Underwriting focus:

• Contracting power, cost of goods, manufacturing scale, and supply uptime.
• Ability to maintain working capital and reduce expiry/waste risk.
• Any defensible difference in formulation stability, packaging convenience, or distribution reach.

Scenario B: Niche brand survival (moderate margin, localized moat)

When it fits:

• Product remains preferred in a limited set of tender regions or care pathways.
• Remaining exclusivity exists at least regionally or the label is still defensible.

Underwriting focus:

• Geographic concentration strategy.
• Tender win rate and price concessions.
• Pharmacovigilance and supply continuity.

Scenario C: IP-protected late lifecycle (high margin, time-bounded moat)

When it fits:

• Specific patents still enforceable for this exact salt/prodrug form, dosing, crystalline form, or manufacturing method.
• Regulatory exclusivity exists due to a modernized submission for the same product.

Underwriting focus:

• Timelines to expiry and injunction risk.
• Evidence that the competitive generic product infringes (or not).
• Probability of successful life-cycle enforcement in chosen jurisdictions.

Key point for investors: The scenario that governs returns is determined by validated IP status and current generic penetration by geography, not by the antibiotic class alone.

---

What market and competitor signals should be treated as “investment-grade”?

For erythromycin gluceptate, investment-grade signals are:

1. Generic penetration by strength and pack size
   Track which strengths and dosage forms have multiple approved suppliers.

2. Formulary and tender behavior
   Monitor procurement cycles and price resets, especially for hospital and institutional channels.

3. Price index trends versus competing macrolides
   Identify whether the product holds a premium due to stability, patient adherence, or tender preference. In antibiotics, premiums rarely persist without IP.

4. Exclusivity and enforcement status
   Whether any granted patents for erythromycin gluceptate are still active in relevant geographies.

Without these signals, a “fundamentals analysis” cannot be translated into a defensible valuation stance.

---

What is the investment thesis conclusion under required constraints?

A complete, investment-ready fundamentals memo for erythromycin gluceptate depends on confirmed:

• the exact marketed product version,
• the geographic scope,
• the enforceable patent/exclusivity status,
• and competitive approvals and penetration in those geographies.

The prompt does not provide any of those elements, so a complete and accurate response cannot be produced under the constraints.

---

Key Takeaways

• Erythromycin gluceptate is a mature macrolide prodrug/salt product type, where investment outcomes usually hinge on IP enforceability and generic penetration rather than intrinsic clinical novelty.
• Antibiotic economics are structurally exposed to tender pricing and substitution among macrolides and generic erythromycin formulations.
• A decision-grade underwriting requires validated exclusivity status by geography and strength, plus current market share and tender behavior. Without those inputs, a complete investment scenario cannot be stated as fact.

---

FAQs

1) Is erythromycin gluceptate typically protected by strong long-term patent estates?

For mature erythromycin products, durable protection is uncommon unless there is a later, enforceable life-cycle patent tied to the exact salt/formulation/process and still active in the target jurisdictions.

2) What most quickly erodes returns for oral antibiotic products like this?

Generic substitution and tender-driven price resets, which compress margins once multiple suppliers are available.

3) Do indications materially change underwriting risk for erythromycin gluceptate?

Yes. Broader, guideline-supported indications can stabilize demand, while narrower indications can accelerate volume volatility.

4) What operational factors matter most if exclusivity is limited?

Manufacturing cost, supply reliability, and distribution execution tied to tender schedules and batch/expiry risk.

5) What should be the first datapoints in an IP-based investment model?

Active patent/exclusivity dates by jurisdiction for the specific marketed salt/dosage form, plus competitor approval timelines and documented bioequivalence/regulatory pathways.

---

References

[1] FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm (accessed 2026-04-25).